Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: From bedside to bench and back

Tumori

Volumn 99, Issue 1, 2013, Pages 10-16

  Yilmaz, Yusuf ^a   Colak, Yasar ^a   Kurt, Ramazan ^b   Senates, Ebubekir ^c   Eren, Fatih ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b ISTANBUL MEDENIYET UNIVERSITY   (Turkey)

^c DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Adipokines; Hepatocellular carcinoma; Insulin resistance; Nonalcoholic fatty liver disease

Indexed keywords

ADIPOCYTOKINE; ANTIDIABETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN;

CELL TRANSFORMATION; EXERCISE; FATTY LIVER; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NONALCOHOLIC FATTY LIVER; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; VASCULARIZATION; WEIGHT REDUCTION;

ADIPOKINES; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; EXERCISE; FATTY LIVER; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN RESISTANCE; LIVER NEOPLASMS; METFORMIN; NEOVASCULARIZATION, PATHOLOGIC; WEIGHT LOSS;

MLCS; MLOWN;

EID: 84878161368     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161309900102     Document Type: Review

References (89)

1. Law K, Brunt EM: Nonalcoholic fatty liver disease. Clin Liver Dis, 14: 591-604, 2010.
2. Krawczyk M, Bonfrate L, Portincasa P: Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol, 24: 695-708, 2010.
3. Cheung O, Sanyal AJ: Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol, 26: 202-208, 2010.
4. Brunt EM, Tiniakos DG: Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol, 16: 5286-5296, 2010.
5. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology, 40: 1387-1395, 2004.
6. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M: Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med, 27: 142-149, 1988.
7. Carulli L, Lonardo A, Lombardini S, Marchesini G, Loria P: Gender, fatty liver and GGT. Hepatology, 44: 278-279, 2006.
8. Suzuki A, Abdelmalek MF: Nonalcoholic fatty liver disease in women. Womens Health (Lond Engl), 5: 191-203, 2009.
9. Adams LA, Lindor KD: Nonalcoholic fatty liver disease. Ann Epidemiol, 17: 863-869, 2007.
10. Kantartzis K, Gastaldelli A, Magkos F, Lavoie JM: Diabetes and nonalcoholic fatty liver disease. Exp Diabetes Res, 2012: 404632, 2012.
11. Smith BW, Adams LA: Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol, 7: 456-465, 2011.
12. Moore JB: Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc, 69: 211-220, 2010.
13. Fabbrini E, Sullivan S, Klein S: Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology, 51: 679-689, 2010.
14. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK: Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol, 6: 1396-1402, 2008.
15. de Freitas AC, Campos AC, Coelho JC: The impact of bariatric surgery on nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care, 11: 267-274, 2008.
16. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G: Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des, 16: 1941-1951, 2010.
17. Almeda-Valdés P, Cuevas-Ramos D, Aguilar-Salinas CA: Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol, 8: S18-24, 2009.
18. Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH: Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond), 116: 539-564, 2009.
19. Pettinelli P, Obregón AM, Videla LA: Molecular mechanisms of steatosis in nonalcoholic fatty liver disease. Nutr Hosp, 26: 441-450, 2011.
20. Mehta K, Van Thiel DH, Shah N, Mobarhan S: Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev, 60: 289-293, 2002.
21. Zhan YT, An W: Roles of liver innate immune cells in nonalcoholic fatty liver disease. World J Gastroenterol, 16: 4652-4660, 2010.
22. Basaranoglu M, Kayacetin S, Yilmaz N, Kayacetin E, Tarcin O, Sonsuz A: Understanding mechanisms of the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol, 16: 2223-2226, 2010.
23. Tessari P, Coracina A, Cosma A, Tiengo A: Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis, 19: 291-302, 2009.
24. Starley BQ, Calcagno CJ, Harrison SA: Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology, 51: 1820-1832, 2010.
25. Petta S, Craxì A: Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association. Curr Pharm Des, 16: 741-752, 2010.
26. Chávez-Tapia NC, Méndez-Sánchez N, Uribe M: Role of nonalcoholic fatty liver disease in hepatocellular carcinoma. Ann Hepatol, 8: S34-39, 2009.
27. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM: Obesity and hepatocellular carcinoma. Gastroenterology, 127 (5 Suppl 1): S97-103, 2004.
28. El-Serag HB: Hepatocellular carcinoma. N Engl J Med, 365: 1118-1127, 2011.
29. Sherman M: Hepatocellular carcinoma: screening and staging. Clin Liver Dis, 15: 323-334, 2011.
30. McGlynn KA, London WT: The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis, 15: 223-243, 2011.
31. Das D, Chattopadhyay D, Aslam T, Patanwala I, Walia D, Rose J, Jaques B, Manas D, Hudson M, Reeves H: NAFLD and the changing face of hepatocellular cancer (HCC). Gut, 60: A243, 2011.
32. Savage DB, Semple RK: Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance. Curr Opin Lipidol, 21: 329-336, 2010.
33. Abdelmalek MF, Diehl AM: Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am, 91: 1125-1149, 2007.
34. Muntoni S, Muntoni S: Insulin resistance: pathophysiology and rationale for treatment. Ann Nutr Metab, 58: 25-36, 2011.
35. Salmon D, Bani-Sadr F, Loko MA, Stitou H, Gervais A, Durant J, Rosenthal E, Quertainmont Y, Barange K, Vittecoq D, Shoai-Tehrani M, Alvarez M, Winnock M, Trinchet JC, Dabis F, Sogni P: Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: Results from ANRS CO13 HEPAVIH. J Hepatol, 56: 862-868, 2012.
36. Mohamed AA, Loutfy SA, Craik JD, Hashem AG, Siam I: Chronic hepatitis C genotype-4 infection: role of insulin resistance in hepatocellular carcinoma. Virol J, 8: 496, 2011.
37. Hung CH, Wang JH, Hu TH, Chen CH, Chang KC, Yen YH, Kuo YH, Tsai MC, Lu SN, Lee CM: Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol, 16: 2265-2271, 2010.
38. Imai K, Takai K, Nishigaki Y, Shimizu S, Naiki T, Hayashi H, Uematsu T, Sugihara J, Tomita E, Shimizu M, Nagaki M, Moriwaki H: Insulin resistance raises the risk for recurrence of stage I hepatocellular carcinoma after curative radiofrequency ablation in hepatitis C virus-positive patients: A prospective, case series study. Hepatol Res, 40: 376-382, 2010.
39. Siddique A, Kowdley KV: Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis, 15: 281-296, 2011.
40. Wu J, Zhu AX: Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol, 4: 30, 2011.
41. Breuhahn K, Schirmacher P: Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma. World J Gastroenterol, 14: 1690-1698, 2008.
42. Chen YW, Boyartchuk V, Lewis BC: Differential roles of insulin-like growth factor receptor-and insulin receptor-mediated signaling in the phenotypes of hepatocellular carcinoma cells. Neoplasia, 11: 835-845, 2009.
43. Yamaguchi M, Tate G, Yoshizawa Y, Midorikawa T, Sanada Y, Kumada K: Hepatocellular carcinoma in a patient with acromegaly and high serum levels of insulin-like growth factor I: report of a case. Surg Today, 32: 1008-1011, 2002.
44. Buechler C, Wanninger J, Neumeier M: Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol, 17: 2801-2811, 2011.
45. Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ: Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm, 2009: 831670, 2009.
46. Mirza MS: Obesity, visceral fat, and NAFLD: querying the role of adipokines in the progression of nonalcoholic fatty liver disease. ISRN Gastroenterol, 2011: 592404, 2011.
47. Wang SN, Wang ST, Lee KT: The potential interplay of adipokines with toll-like receptors in the development of hepatocellular carcinoma. Gastroenterol Res Pract, 2011: 215986, 2011.
48. Arano T, Nakagawa H, Tateishi R, Ikeda H, Uchino K, Enooku K, Goto E, Masuzaki R, Asaoka Y, Kondo Y, Goto T, Shiina S, Omata M, Yoshida H, Koike K: Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients. Int J Cancer, 129: 2226-2235, 2010.
49. Wang SN, Lee KT, Ker CG: Leptin in hepatocellular carcinoma. World J Gastroenterol, 16: 5801-5809, 2010.
50. Lemoine M, Ratziu V, Kim M, Maachi M, Wendum D, Paye F, Bastard JP, Poupon R, Housset C, Capeau J, Serfaty L: Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int, 29: 1431-1438, 2009.
51. Zhou J, Lei W, Shen L, Luo HS, Shen ZX: Primary study of leptin and human hepatocellular carcinoma in vitro. World J Gastroenterol, 14: 2900-2904, 2008.
52. Sharma D, Wang J, Fu PP, Sharma S, Nagalingam A, Mells J, Handy J, Page AJ, Cohen C, Anania FA, Saxena NK: Adi po ne -ctin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology, 52: 1713-1722, 2010.
53. Trinchieri G: Inflammation in cancer: a therapeutic target? Oncology (Williston Park), 25: 418-420, 2011.
54. Sgambato A, Cittadini A: Inflammation and cancer: a multifaceted link. Eur Rev Med Pharmacol Sci, 14: 263-268, 2010.
55. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell, 140: 883-899, 2010.
56. Tilg H, Moschen AR: Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology, 52: 1836-1846, 2010.
57. Byrne CD: Fatty liver: role of inflammation and fatty acid nutrition. Prostaglandins Leukot Essent Fatty Acids, 82: 265-271, 2010.
58. Tilg H, Moschen AR: Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab, 19: 371-379, 2008.
59. Targher G: Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with nonalcoholic fatty liver disease. J Hepatol, 45: 879-881, 2006.
60. Devaraj S, Singh U, Jialal I: Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol, 20: 182-189, 2009.
61. Nagaoka S, Yoshida T, Akiyoshi J, Akiba J, Torimura T, Adachi H, Kurogi J, Tajiri N, Inoue K, Niizeki T, Koga H, Imaizumi T, Kojiro M, Sata M: Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int, 27: 1091-1097, 2007.
62. Wada H, Satoh N, Kitaoka S, Ono K, Morimoto T, Kawamura T, Nakano T, Fujita M, Kita T, Shimatsu A, Hasegawa K: Soluble VEGF receptor-2 is increased in sera of subjects with metabolic syndrome in association with insulin resistance. Atherosclerosis, 208: 512-517, 2010.
63. Seeley RJ: Treating obesity like a tumor. Cell Metab, 15: 1-2, 2012.
64. Cao Y: Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nat Rev Drug Discov, 9: 107-115, 2010.
65. Ribatti D, Conconi MT, Nussdorfer GG: Nonclassic endogenous novel [corrected] regulators of angiogenesis. Pharmacol Rev, 59: 185-205, 2007.
66. Gaudry M, Brégerie O, Andrieu V, El Benna J, Pocidalo MA, Hakim J: Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood, 90: 4153-4161, 1997.
67. Semela D, Dufour JF: Angiogenesis and hepatocellular carcinoma. J Hepatol, 41: 864-880, 2004.
68. Finn RS, Zhu AX: Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther, 9: 503-509, 2009.
69. Blann AD: Angiogenesis, the metabolic syndrome and heart disease: is there a connection? J Intern Med, 268: 312-315, 2010.
70. Tilg H, Moschen A: Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol, 56: 159-167, 2010.
71. Patel AA, Torres DM, Harrison SA: Effect of weight loss on nonalcoholic fatty liver disease. J Clin Gastroenterol, 43: 970-974, 2009.
72. Rafiq N, Younossi ZM: Effects of weight loss on nonalcoholic fatty liver disease. Semin Liver Dis, 28: 427-433, 2008.
73. Polyzos SA, Kountouras J, Zavos C, Tsiaousi E: The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab, 12: 365-383, 2010.
74. Sofer E, Boaz M, Matas Z, Mashavi M, Shargorodsky M: Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. Metabolism, 60: 1278-1284, 2011.
75. Duseja A, Das A, Dhiman RK, Chawla YK, Thumburu KT, Bhadada S, Bhansali A: Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol, 6: 222-226, 2007.
76. Nadeau KJ, Ehlers LB, Zeitler PS, Love-Osborne K: Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatr Diabetes, 10: 5-13, 2009.
77. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G: Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int, 30: 750-758, 2010.
78. Pais R, Moraru I, Ratziu V: Glitazones for human nonalcoholic steatohepatitis. Therap Adv Gastroenterol, 4: 325-334, 2011.
79. Shadid S, Jensen MD: Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity. Clin Gastroenterol Hepatol, 1: 384-387, 2003.
80. Tolman KG, Freston JW, Kupfer S, Perez A: Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf, 32: 787-800, 2009.
81. Saryusz-Wolska M, Szymaska-Garbacz E, Jabłkowski M, Białkowska J, Pawłowski M, Kwieciska E, Omulecka A, Borkowska A, Ignaczak A, Loba J, Czupryniak L: Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease. Pol Arch Med Wewn, 121: 61-66, 2011.
82. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Arnold Chan K: Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology, 55: 1462-1472, 2012.
83. Musso G, Cassader M, Gambino R: Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update. Curr Opin Lipidol, 22: 489-496, 2011.
84. Riley P, Sudarshi D, Johal M, Benedict A, Panteli J, Crook M, O'Donohue J: Weight loss, dietary advice and statin thera-py in non-alcoholic fatty liver disease: a retrospective study. Int J Clin Pract, 62: 374-381, 2008.
85. Zhang W, Wu J, Zhou L, Xie HY, Zheng SS: Fluvastatin, a lipophilic statin, induces apoptosis in human hepatocellular carcinoma cells through mitochondria-operated pathway. Indian J Exp Biol, 48: 1167-1174, 2010.
86. Relja B, Meder F, Wang M, Blaheta R, Henrich D, Marzi I, Lehnert M: Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK. Int J Oncol, 38: 879-885, 2011.
87. El-Serag HB, Johnson ML, Hachem C, Morgana RO: Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology, 136: 1601-1608, 2009.
88. Yilmaz Y, Atug O, Yonal O, Duman D, Ozdogan O, Imeryuz N, Kalayci C: Dipeptidyl peptidase IV inhibitors: therapeutic potential in nonalcoholic fatty liver disease. Med Sci Monit, 15: HY1-5, 2009.
89. Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ: Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int, 26: 1015-1017, 2006.